Jing Li

This inventor holds 12 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2012-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jing Li. Retrieved from https://idiyas.com/inventor/jing-li-5w68toy2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 157(Granted Patents)

Location History:

College Station, MA (US) (2012)
College Station, TX (US) (2013)
Andover, MA (US) (2015 - 2022)

Company Filing History:

12 out of 530

Eisai R&d Management Co., Ltd.

patents

Years Active: 2012-2022

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11434246 - EP4 antagonists (2022-09-06),

2. 10941148 - EP4 antagonists (2021-03-09),

3. 10717743 - Intermediates and methods for the synthesis of halichondrin B analogs (2020-07-21),

4. 10548986 - Eribulin-based antibody-drug conjugates and methods of use (2020-02-04),

5. 10322192 - Eribulin-based antibody-drug conjugates and methods of use (2019-06-18),

6. 10316040 - EP4 antagonists (2019-06-11),

7. 10214539 - Intermediates and methods for the synthesis of halichondrin B analogs (2019-02-26),

8. 9802953 - Intermediates and methods for the synthesis of halichondrin B analogs (2017-10-31),

9. 9604993 - Intermediates and methods for the synthesis of halichondrin B analogs (2017-03-28),

10. 8987479 - Intermediates and methods for the synthesis of halichondrin B analogs (2015-03-24),

11. 8350059 - Intermediates and methods for making zearalenone macrolide analogs (2013-01-08),

12. 8093410 - Intermediates and methods for the synthesis of halichondrin B analogs (2012-01-10),

Title: The Innovative Contributions of Inventor Jing Li

Introduction

Jing Li, an accomplished inventor based in Andover, MA, has made significant strides in the field of pharmaceutical research and development. With a total of 12 patents to her name, she is recognized for her contributions to cancer treatment through innovative compounds.

Latest Patents

Among her latest patents, Jing Li focuses on EP4 antagonists. These patents detail compounds represented by Formula I, alongside pharmaceutically acceptable salts and their formulations. The detailed methods of use for these compounds aim at advancing cancer treatment, showcasing her commitment to improving healthcare outcomes.

Career Highlights

Jing Li is currently employed at Eisai R&D Management Co., Ltd., a company well-regarded for its contributions to medical science and patient care. Her work at this organization has been pivotal in developing new therapeutic strategies for serious health conditions.

Collaborations

Throughout her career, Jing Li has collaborated with several prominent professionals, including Francis Gerard Fang and Charles E. Chase. These partnerships reflect her dedication to advancing pharmaceutical research through collective expertise.

Conclusion

Jing Li's innovative patents and collaborative efforts in developing treatments for cancer underscore her significant role as an inventor in the pharmaceutical industry. Her commitment to advancing medical science positions her as a valuable asset in the ongoing fight against cancer.

Profile summary based on public USPTO records.